Biomarker out-licensing
SphingoTec offers out-licensing opportunities for its proprietary, clinically validated biomarkers to diagnostics and medical technology companies worldwide. By partnering with SphingoTec, licensees gain access to innovative biomarker assays addressing diagnostically underserved acute and critical care conditions, such as acute kidney injury, sepsis, and acute heart failure.
Pharma Collaborations
Our diagnostic solutions address critical disease pathways, for which other companies develop treatments. The use of biomarkers to identify treatment responders and non-responders becomes increasingly important. Our biomarkers can provide a solution for enrichment and increased efficacy strategies in critical care drug discovery to de-risk drug developments.
Service measurements
SphingoTec develops and markets innovative biomarkers for acute medical conditions. For clinical studies, we not only make available our biomarkers as microtiter plate (MTP) assays, but together with partner laboratories, we also offer service measurements to our clinical and research partners. Our custom testing services can be tailored to meet the experimental requirements of our partners, thus saving time and resources.
